Mirna Therapeutics to Host Conference Call and Webcast of Fourth Quarter and Full Year 2015 Financial Results on March 29, 2016
March 22 2016 - 7:35AM
Business Wire
Mirna Therapeutics, Inc. (Nasdaq:MIRN), a clinical-stage
biopharmaceutical company developing a broad pipeline of
microRNA-based oncology therapeutics, today announced that the
Company will host a conference call and live webcast on Tuesday,
March 29, 2016 at 5:00 p.m. ET to report its fourth quarter and
full year 2015 financial results and provide a clinical program and
business update.
To access the call, participants should dial 877-407-9079 (US
& Canada) or 201-493-6746 (international) at least 10 minutes
prior to the start of the call. The call will be webcast live and
may be accessed from the Events & Presentations section of the
Company's website. An archived version of the webcast will be
available for replay following the event.
About Mirna Therapeutics, Inc.
Mirna is a clinical-stage biopharmaceutical company developing a
broad pipeline of microRNA-based oncology therapeutics and is the
first to establish clinical proof-of-concept for a microRNA
replacement therapy for cancer. Mirna's lead product candidate,
MRX34, a mimic of naturally occurring microRNA-34 (miR-34), is
currently being studied in a Phase 1 clinical trial in patients
with primary liver cancer, advanced solid tumors and hematological
malignancies. miR-34 is one of the most widely published microRNAs
and is considered a key regulator of multiple oncogenes across key
oncogenic pathways, with the capacity to regulate more than 30
different oncogenes and repress the immune checkpoint signaling
molecule PD-L1. The potential capacity to simultaneously affect
multiple pathways and processes that are critical to cancer cell
viability may make mimics of tumor suppressor microRNAs potent
anti-cancer agents and less susceptible to drug resistance. Mirna
plans to develop MRX34 as a monotherapy and in combination with
other therapeutic modalities, such as targeted therapies and
immuno-oncology agents. The Company was founded in 2007 and is
located in Austin, Texas.
For more information, visit www.mirnarx.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160322005745/en/
InvestorsThe Trout GroupJosh Barer,
646-378-2948jbarer@troutgroup.comorMediaBMC
CommunicationsAmy Bonanno,
646-513-3117abonanno@bmccommunications.com
MIRNA THERAPEUTICS, INC. (NASDAQ:MIRN)
Historical Stock Chart
From Apr 2024 to May 2024
MIRNA THERAPEUTICS, INC. (NASDAQ:MIRN)
Historical Stock Chart
From May 2023 to May 2024